Description     Claims     Drawing  

US75263405P   [0001] 
US5278161A   [0003] 
US2003181455A   [0003] 
US6355798B   [0003] 
WO2005002590A   [0003] 
US2005096322A   [0003] 
US2004192696A   [0003]  [0004] 
US4810705A   [0004] 
DE2222834   [0004] 
US3823137A   [0004]  [0004] 
DE2147013   [0004] 
US3919200A   [0004] 
DE2113438   [0004] 
DE2030581   [0004] 
DE1670160   [0004] 
US3506656A   [0004] 
DE1545598   [0004] 
US3483193A   [0004] 
DE2161587   [0004] 
DE4309285   [0004] 
WO2004021984A   [0004] 
US2004147568A   [0004] 
JP63199347B   [0004] 
WO1999037303A   [0004] 
US6297235B   [0004] 
US6444666B   [0004] 
WO2001034603A   [0004] 
WO2004017950A   [0004] 
CA2132489   [0004] 
WO2004058769A   [0004] 
WO2003074525A   [0004]  [0004] 
WO2003032916A   [0004] 
JP62147775A   [0004] 
US4260755A   [0004] 
WO2002012236A   [0004] 
EP464572A   [0004] 
EP404190A   [0004] 
EP156734A   [0004] 
WO200501005A   [0004] 
WO2005004607A   [0004] 
WO2005004808A   [0004] 
JP63310891B   [0004] 
EP1229034A1   [0083] 
EP20020807A   [0083] 
WO0006566A   [0083] 
WO2002085888A   [0085] 
US6776796B   [0559] 
WO9632907A   [0560] 
US20020016625A   [0560] 
US5855866A   [0569]  [0569] 
US6342219B   [0569] 
US5474765A   [0571]  [0571] 
US5762918A   [0571]  [0571] 

Science of Synthesis   [0003] 
Heterocycles   [0003] 
Heterocycles   [0003] 
Journal of Heterocyclic Chemistry   [0003] 
Tetrahedron   [0003] 
Synthesis of new s-triazolo[4,3-b]pyridazines   [0004] 
Synthetic reactions and structural studies of heterocycles containing nitrogen. Part 14. Dehydration of 2-(2-arylethyl)-2-hydroxy-4-oxopentanoic acids and their hydrazones to form heterocycles   [0004] 
Synthesis of s-triazolo[4,3-b]pyridazine C-nucleosides (1)   [0004] 
Synthesis and anxiolytic activity of 6-(substituted-phenyl)-1,2,4-triazolo[4,3-b]pyridazines   [0004] 
Thermal cyclization of pyridazinylhydrazones to give s-triazolo[4,3-b]pyridazines and pyridazino[2,3-a]benzimidazole,'' Journal of the Chemical Society   [0004] 
Synthesis and study of the antitubercular activity of 2-(5-nitro-2-furyl)vinyl derivatives of pyridazine and s-triazolo[4,3-b]pyridazine   [0004] 
Synthesis of new 1,2,4-triazolo[4,3-b]pyridazines and related compounds   [0004] 
The synthesis ofN-phthaloyl-azatryptophan derivatives   [0004] 
Synthesis of 3-(a- and b-D-arabinofuranosyl)-6-chloro-1,2,4-triazolo[4,3-b]pyridazine   [0004] 
Synthesis of novel [1,2,4]triazolo[4,3-b]pyridazines   [0004] 
A simple one pot synthesis of 1-(s-triazolo[4,3-x]azinyl-3)-substituted polyols   [0004] 
Preparation of new [1,2,4]triazolo[4,3-b]pyridazines. Part 12: Studies in the field of pyridazine compounds   [0004] 
Studies in the field of pyridazine compounds. II. Derivatives of [1,2,4]triazolo[4,3-b]pyridazine-3-carboxylic acid   [0004] 
Product class 1: pyrazoles   [0004] 
Transformation of N-(5-acetyl-6-methyl-2-oxo-2H-pyran-3-yl)benzamide with hydrazines in the presence of an acidic catalyst   [0004] 
Synthesis and reactivity of (Z)-3-benzoylamino-4-dimethylamino-2-oxo-3- butene. Preparation of 1-aryl- and 1-heteroaryl-substituted 4-benzoylamino-5-methyl-1H-pyrazoles   [0004] 
Transformation of 4-[1-(dimethylamino)ethylidene]-2-phenyl-5(4H)-oxazolone into methyl 2-(benzoylamino)-3-oxobutanoate. The synthesis of 1-substituted 4-(benzoylamino)-3-methyl-5(2H)-pyrazolones   [0004] 
2H-Pyran-2-ones as synthons for (E)-α,β-didehydroamino acid derivatives   [0004] 
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition   [0010] 
Infrequent mutations of the MET gene in sporadic breast tumours (letter)   [0010] 
Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma   [0010] 
c-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favourable prognostic factors in invasive breast carcinoma   [0010] 
Over-expression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas   [0010] 
Clinical significance of c-met oncogene alterations in human colorectal cancer   [0010] 
Frequent amplification of the c-met gene in scirrhous type stomach cancer   [0010] 
Aberrant expression of c-met mRNA in human gastric carcinomas   [0010] 
Absence of mutations in the kinase domain of the Met gene and frequent expression of Met and HGF/SF protein in primary gastric carcinomas   [0010] 
A novel germ line juxtamembrane Met mutation in human gastric cancer   [0010] 
Concomitant expression of hepatocyte growth factor (HGF), HGF activator and c-met genes in human glioma cells in vitro   [0010] 
Missense mutation of the MET gene detected in human glioma   [0010] 
Somatic mutations of the met oncogene are selected during metastatic spread of human HNSC carcinomas   [0010] 
Expression of the c-met proto-oncogene in human hepatocellular carcinoma   [0010] 
Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas   [0010] 
Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene   [0010] 
Duplication and over-expression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours   [0010] 
Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas   [0010] 
Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family   [0010] 
Novel mutations of the MET proto-oncogene in papillary renal carcinomas   [0010] 
The Met/hepatocyte growth factor receptor (HGFR) gene is over-expressed in some cases of human leukemia and lymphoma   [0010] 
Hepatocyte growth factor/scatter factor and its receptor c-Met are over-expressed and associated with an increased microvessel density in malignant pleural mesothelioma   [0010] 
Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c-met receptor   [0010] 
Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas   [0010] 
Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression   [0010] 
Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease   [0010] 
In vitro and in vivo expression of transforming growth factor-alpha and tyrosine kinase receptors in human non-small-cell lung carcinomas   [0010] 
Over-expression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas   [0010] 
Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance   [0010] 
Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers   [0010] 
The clinical significance of hepatocyte growth factor for non-small cell lung cancer   [0010] 
c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma   [0010] 
The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit   [0010] 
Over-expression of the Met/HGF receptor in ovarian cancer   [0010] 
Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells   [0010] 
Co-expression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer   [0010] 
c-met proto-oncogene expression in benign and malignant human prostate tissues   [0010] 
Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma   [0010] 
Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts   [0010] 
Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcoma   [0010] 
Over-expression of the c-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium   [0010] 
Independent prognostic value of serum hepatocyte growth factor in bladder cancer   [0010] 
Targeting the tumor and its microenvironment by a dual-function decoy Met receptor   [0011] 
The HGF Receptor c-Met Is Overexpressed in Esophageal Adenocarcinoma.   [0013] 
Immunoblot analysis of c-Met expression in human colorectal cancer: overexpression is associated with advanced stage cancer   [0013] 
Expression and correlation of c-Met and estrogen receptor in endometrial carcinomas] Sichuan Da Xue Xue Bao Yi Xue Ban   [0013] 
Hepatocyte growth factor and c-Met immunoreactivity are associated with metastasis in high grade salivary gland carcinoma   [0013] 
Prognostic significance of hepatocyte growth factor and c-MET expression in patients with diffuse large B-cell lymphoma   [0013] 
C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu   [0013] 
Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms   [0013] 
Prostate cancer and the met hepatocyte growth factor receptor   [0013] 
The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients   [0013] 
C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu   [0013] 
Nomenclature of Organic Chemistry   [0038] 
A Guide to IUPAC Nomenclature of Organic Compounds (Recommendations 1993)   [0038] 
Ref. International J. Pharm.   [0054] 
J. Pharm. Sci.   [0054] 
IUPAC Recommendations for Fundamental Stereochemistry   [0072] 
Protecting Groups   [0078] 
Protective Groups in Organic Synthesis   [0078] 
Chem. Rev.   [0080]  [0091] 
J. Org. Chem.   [0080]  [0091] 
Agnew. Chem., Int. Ed. Engl.   [0080] 
J. Med. Chem.   [0080] 
Chemistry - A European Journal   [0082] 
Journal of Medicinal Chemistry   [0083] 
Bioorganic and Medicinal Chemistry Letters   [0083] 
Tetrahedron Letters   [0083] 
Synthetic Communications   [0083] 
Journal of Medicinal Chemistry   [0083] 
Journal of Medicinal Chemistry   [0083] 
Bioorganic and Medicinal Chemistry Letters   [0083] 
Organic Letters   [0083] 
Helvitica Chemica Acta   [0083] 
Journal of Medicinal Chemistry   [0085] 
Bulletin de la Societe Chimique de France   [0086] 
Helvitica Chemica Acta   [0086] 
Chemische Berichte   [0088] 
Australian Journal of Chemistry   [0088] 
Bioorganic and Medicinal Chemistry Letters   [0088] 
Agnew. Chem.   [0091] 
Org. Lett.   [0139] 
J. Med. Chem.   [0236] 
Proc Natl Acad Sci USA   [0471] 
Critical Reviews in Oncology/Hematology   [0483] 
The calcium channel blocker verapamil and cancer chemotherapy   [0522] 
Vascular restenosis - striving for therapy   [0563] 
Hepatocyte growth factor triggers signaling cascades mediating vascular smooth muscle cell migration   [0563] 
Hepatocyte growth factor as cardiovascular hormone: role of HGF in the pathogenesis of cardiovascular disease   [0563] 
Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy   [0570] 
Antibodies For Drug Delivery   [0570] 
Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review   [0570]